Aripiprazole Augmentation of Antidepressants in PTSD
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The proposed investigation will determine the therapeutic potential of aripiprazole
augmentation to a stable antidepressant regimen for reducing posttraumatic stress disorder
(PTSD) symptoms, cognitive symptoms, psychotic symptoms, and depressive symptoms in veterans
with PTSD.